A Phase 2 Study of ARQ 197 in Patients With Previously-Treated Malignant Mesothelioma
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Tivantinib (Primary)
- Indications Malignant-mesothelioma
- Focus Therapeutic Use
- 23 Nov 2015 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov record
- 02 Jun 2015 Primary endpoint has not been met. (Objective radiologic response rate (complete or partial response) assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1) according to an abstract presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.